# Heart rate variability analysis using electrocardiograms during cardio-ankle vascular index measurement shows good agreement with resting electrocardiogram-based analysis in patients with diabetes: a retrospective cross-sectional study

**Authors:** Yuka Shibata, Toshiki Kiyose, Tatsuhito Himeno, Masahiro Shimoda, Hirohiko Ando, Ayako Ito, Atsuo Itani, Toru Shimizu, Rion Miura, Mika Matsuoka, Kento Tsuzuki, Takahiro Shinozaki, Mikio Motegi, Tomohide Hayami, Hiromi Nakai-Shimoda, Makoto Kato, Emiri Miura-Yura, Takayuki Nakayama, Yoshiaki Morishita, Masaki Kondo, Shin Tsunekawa, Jiro Nakamura, Tetsuya Amano, Hideki Kamiya

PMC · DOI: 10.1007/s13340-025-00869-z · 2026-01-21

## TL;DR

The study shows that heart rate variability analysis during a vascular test can reliably assess nerve damage in diabetes patients.

## Contribution

The study demonstrates that HRV analysis during CAVI measurement is a practical alternative to resting HRV assessment for detecting CAN in diabetes.

## Key findings

- HF power of HRV during CAVI measurement showed good agreement with resting HRV analysis.
- Diabetic patients had significantly lower HRV, especially high-frequency power and RR interval variation.
- HRV parameters did not correlate with the severity of sensorimotor polyneuropathy.

## Abstract

Cardiovascular autonomic neuropathy (CAN) is a common but underrecognized diabetic complication. Although heart rate variability (HRV) analysis is a less invasive alternative to cardiovascular autonomic reflex tests, it is not routinely performed due to time and equipment constraints. This study aimed to assess whether HRV analysis using electrocardiograms (ECG) recorded during cardio-ankle vascular index (CAVI) measurement can serve as a practical substitute for conventional resting ECG-based HRV assessment.

This cross-sectional study enrolled 48 patients with diabetes and 20 healthy controls. HRV spectral indices were calculated from ECG recorded during both resting (3-min HRV) and CAVI measurement (CAVI-HRV). Agreement between HRV indices obtained under different conditions was evaluated by intraclass correlation coefficients and Bland–Altman analyses. Correlations between HRV parameters and clinical indices were examined. Participants with diabetes showed significantly lower HRV (especially high-frequency power), and reduced coefficient of variation of RR intervals. HF power of CAVI-HRV showed good agreement with 3-min HRV, whereas LF power showed only moderate concordance. HRV spectral parameters did not significantly correlate with severity of sensorimotor polyneuropathy.

HRV analysis performed during CAVI measurement reliably assesses parasympathetic function in diabetes. This approach may provide a convenient, accessible strategy for early CAN screening.

## Linked entities

- **Diseases:** diabetes (MONDO:0005015)

## Full-text entities

- **Genes:** ALB (albumin) [NCBI Gene 213] {aka FDAHT, HSA, PRO0883, PRO0903, PRO1341}
- **Diseases:** nerve conduction abnormality (MESH:D054537), diabetic autonomic neuropathy (MESH:D003929), neuropathy (MESH:D009422), sexual dysfunction (MESH:D012735), arterial stiffness (MESH:C566112), NCS (MESH:C537568), gastrointestinal dysmotility (MESH:D015154), TBI (MESH:D000070592), autonomic dysfunction (MESH:D001342), resting tachycardia (MESH:D013610), arteriosclerosis (MESH:D001161), nephropathy (MESH:D007674), polyneuropathy (MESH:D011115), diabetes (MESH:D003920), metabolic syndrome (MESH:D024821), atrial fibrillation (MESH:D001281), orthostatic symptoms (MESH:D006261), atherosclerosis (MESH:D050197), CAVI (MESH:D016512), diabetic retinopathy (MESH:D003930), CAN (MESH:D002318), diabetic complication (MESH:D048909), HF (MESH:D006316), DM (MESH:D009223)
- **Chemicals:** creatinine (MESH:D003404), alpha-adrenergic or beta-adrenergic blockers (-), uric acid (MESH:D014527), glucose (MESH:D005947), cholesterol (MESH:D002784), triglyceride (MESH:D014280), TC (MESH:D013667), TG (MESH:D013866)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12824053/full.md

---
Source: https://tomesphere.com/paper/PMC12824053